147 related articles for article (PubMed ID: 32623444)
1. Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy.
Østergaard A; Bohnstedt C; Grell K; Degn M; Zeller B; Taskinen M; Hafsteinsdottir S; Björgvinsdóttir H; Heyman M; Hoogerbrugge P; Schmiegelow K;
Leukemia; 2021 Mar; 35(3):863-866. PubMed ID: 32623444
[No Abstract] [Full Text] [Related]
2. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
3. Poor treatment compliance in children with down syndrome and acute lymphoblastic leukemia.
Bohnstedt C; Taskinen M; Zeller B; Björgvinsdóttir H; Hafsteinsdottir S; Schmiegelow K
J Pediatr Hematol Oncol; 2009 Jan; 31(1):79-80. PubMed ID: 19125098
[No Abstract] [Full Text] [Related]
4. Sinusoidal Obstruction Syndrome During Maintenance Therapy for Acute Lymphoblastic Leukemia With 6-Mercaptopurine and Methotrexate: A Pediatric Case Report.
McNerney KO; Vasquez JC; Kent MW; McNamara JM
J Pediatr Hematol Oncol; 2017 Nov; 39(8):e454-e455. PubMed ID: 28085749
[TBL] [Abstract][Full Text] [Related]
5. Intracellular pharmacology and biochemistry of methotrexate and 6-mercaptopurine in childhood acute lymphoblastic leukemia.
Keuzenkamp-Jansen CW; Bökkerink JP; Trijbels JM; vd Heijden MA; De Abreu RA
Adv Exp Med Biol; 1994; 370():115-8. PubMed ID: 7660872
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
[TBL] [Abstract][Full Text] [Related]
7. 6-Mercaptopurine cumulative dose: a critical factor of maintenance therapy in average risk childhood acute lymphoblastic leukemia.
Dibenedetto SP; Guardabasso V; Ragusa R; Di Cataldo A; Miraglia V; D'Amico S; Ippolito AM
Pediatr Hematol Oncol; 1994; 11(3):251-8. PubMed ID: 8060809
[TBL] [Abstract][Full Text] [Related]
8. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
[TBL] [Abstract][Full Text] [Related]
9. Improved prognosis for childhood acute lymphocytic leukemia with very high white blood cell count (greater than 100/nl) with rotation of non-cross-resistant drug combinations.
Janka-Schaub GE; Goebel U; Graubner U; Haas RJ; Juergens H; Spaar HJ; Winkler K
Haematol Blood Transfus; 1990; 33():489-93. PubMed ID: 2182442
[No Abstract] [Full Text] [Related]
10. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia.
Schmiegelow K
Pediatr Hematol Oncol; 1991; 8(4):301-12. PubMed ID: 1782110
[TBL] [Abstract][Full Text] [Related]
12. Intermediate-dose methotrexate and intravenous 6-mercaptopurine chemotherapy for children with acute lymphoblastic leukemia who did not respond to initial induction therapy.
Ogden AK; Pollock BH; Bernstein ML; Camitta B; Buchanan GR
J Pediatr Hematol Oncol; 2002; 24(3):182-7. PubMed ID: 11990303
[TBL] [Abstract][Full Text] [Related]
13. Adherence to Oral Medications During Maintenance Therapy Among Children and Adolescents With Acute Lymphoblastic Leukemia: A Medication Refill Analysis.
Wu YP; Stenehjem DD; Linder LA; Yu B; Parsons BG; Mooney R; Fluchel MN
J Pediatr Oncol Nurs; 2018; 35(2):86-93. PubMed ID: 29188741
[TBL] [Abstract][Full Text] [Related]
14. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome.
Shah N; Al-Ahmari A; Al-Yamani A; Dupuis L; Stephens D; Hitzler J
Pediatr Blood Cancer; 2009 Jan; 52(1):14-9. PubMed ID: 18802938
[TBL] [Abstract][Full Text] [Related]
15. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
16. Maintenance chemotherapy of acute lymphoblastic leukemia in children.
Schmiegelow K
Dan Med Bull; 1998 Nov; 45(5):510-32. PubMed ID: 9850812
[No Abstract] [Full Text] [Related]
17. Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report.
Zawitkowska J; Odój T; Drabko K; Zaucha-Prażmo A; Rudnicka J; Romiszewski M; Matysiak M; Kwiecińska K; Ćwiklińska M; Balwierz W; Owoc-Lempach J; Derwich K; Wachowiak J; Niedźwiecki M; Adamkiewicz-Drożyńska E; Trelińska J; Młynarski W; Kołtan A; Wysocki M; Tomaszewska R; Szczepański T; Płonowski M; Krawczuk-Rybak M; Ociepa T; Urasiński T; Mizia-Malarz A; Sobol-Milejska G; Karolczyk G; Kowalczyk J
Pediatr Hematol Oncol; 2017 May; 34(4):199-205. PubMed ID: 29040012
[TBL] [Abstract][Full Text] [Related]
18. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia.
Gale RP; Butturini A
Lancet; 1991 Nov; 338(8778):1315-8. PubMed ID: 1682696
[TBL] [Abstract][Full Text] [Related]
19. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
[TBL] [Abstract][Full Text] [Related]
20. Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia.
Henze G; Fengler R; Reiter A; Ritter J; Riehm H
Haematol Blood Transfus; 1990; 33():483-8. PubMed ID: 2182441
[No Abstract] [Full Text] [Related]
[Next] [New Search]
